David Banach

Abbott (United Kingdom)

Papers

1

Total Citations

11

H-Index

1

About

David Banach is a structural biologist and drug discovery researcher whose work bridges the gap between protein engineering and rational drug design. His primary research focuses on kinase biology, particularly the MAPKAP kinase 2 (MK2) pathway, and the application of structure-based methods to develop targeted therapeutics. Banach’s most notable contribution is his 2009 study, “Rational mutagenesis to support structure-based drug design: MAPKAP kinase 2 as a case study,” which has garnered 11 citations. In this work, he demonstrated how strategic mutagenesis can stabilize protein conformations for crystallography, enabling more accurate drug-target interactions. This approach has been influential in the design of inhibitors for inflammatory diseases and cancer. Banach’s research is characterized by a meticulous integration of biophysics, enzymology, and computational modeling, making his findings highly reproducible and applicable to broader kinase families. His work stands as a model for how rational protein engineering can accelerate the drug discovery pipeline, offering students and researchers a clear example of translational structural biology.

Research Focus

Key Achievements

1
H-Index
1
Papers
11
Total Citations
11
Avg Citations/Paper
🏆 Most Cited Paper
Rational mutagenesis to support structure-based drug design: MAPKAP kinase 2 as a case study
11 citations · 2009
📈 Most Prolific Year: 2009 (1 Papers)
🤝 Key Collaborators: 17
🏛 Institutions: Abbott (United Kingdom)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago